BIOD : Summary for ALBIREO PHARMA INC - Yahoo Finance

U.S. Markets closed

Biodel Inc. (BIOD)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.65+0.03 (+5.51%)
At close: 4:00 PM EDT
People also watch:
OREXCYCCSNTAAEZSCYTK
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.65
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range0.52 - 0.71
52 Week Range0.22 - 0.80
Volume2,338,156
Avg. Volume952,248
Market Cap41.62M
BetaN/A
PE Ratio (TTM)-0.09
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Albireo Completes Transaction with Biodel to Create Publicly Traded Company Focused on Orphan Pediatric Liver Diseases

    —Albireo Pharma, Inc. to trade on The NASDAQ Capital Market under symbol“ ALBO”—. —Company to develop novel bile acid modulators to treat orphan pediatric liver diseases, other liver and gastrointestinal ...

  • Here Are Three Big Biotech Movers And Our Take On What’s Next
    Insider Monkeylast month

    Here Are Three Big Biotech Movers And Our Take On What’s Next

    So we’re going to close out the week with a roundup of some of the companies that have moved the most over the last couple of sessions, and what’s driving the movement. We’ll also take a stab at detailing what we expect moving forward for each – specifically, will the trend continue, or might the […]

  • PR Newswirelast month

    Biodel Announces Intent to Further Adjourn Annual Meeting until Thursday, November 3

    Biodel notes the following important considerations. The Further Adjournment would be intended to allow additional time for stockholders to vote on the proposals set forth in Biodel's definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on September 19, 2016. As of October 26, 2016, proxies have been submitted by stockholders representing approximately 49.83% of the outstanding shares of Biodel common stock outstanding and entitled to vote at the Annual Meeting, meaning that almost 32.2 million shares remain unvoted.